ESTRO 2025 - Abstract Book

S884

Clinical - Gynaecology

ESTRO 2025

1 Radiation Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain. 2 Radiation Oncology, Hospital Universitario Miguel de Servet, Zaragoza, Spain. 3 Radiation Oncology, Hospital Universitario de Pamplona, Pamplona, Spain Purpose/Objective: To assess the oncologic outcomes and toxicity profile of high-dose-rate interstitial brachytherapy (HDR-BT) with 192Ir combined with external beam radiotherapy (EBRT) in patients with locally advanced cervical cancer (LACC). Material/Methods: Between December 2016 and November 2023, 84 patients with histologically confirmed LACC were treated with intensity-modulated EBRT (45 Gy in 25 fractions) followed by image-guided, adapted HDR-BT (2-4 fractions of 7 Gy). Toxicity was evaluated using the CTCAE v5.0 criteria. Patient characteristics are summarized in Table 1. Results: With a median follow-up of 65 months (range: 6-90), the complete response rate was 78.5% (66/84). Locoregional recurrence occurred in 10.5% (9/84), while 23.8% (20/84) experienced distant recurrence. The median time to local failure was 12 months (range: 6-36). Notably, 11 patients (13.1%) succumbed to cervical cancer. Acute toxicity was primarily grade 1 or 2, with genitourinary (GU) toxicity being most commonly cystitis (56%) and gastrointestinal (GI) toxicity predominantly diarrhea (64.2%). Severe complications were rare: only one patient had grade 3 vaginal stenosis, and two developed grade 2 vesicovaginal fistula requiring local wound care. No grade ≥ 3 late GU or GI toxicities were reported.